Markets:

Overview

News

Currencies

International

Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

36.64 +0.51 (+1.41%)

Official Closing Price Updated: 4:00 PM EDT, May 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement

July 26, 2023

From Bio-Rad Laboratories, Inc.

Via Business Wire

Will Chart Analysts Notice Bad Omen on Qiagen's Chart ↗

April 11, 2023

Via Benzinga

The 3 Most Promising Biotech Stocks to Buy Now ↗

March 21, 2023

With the NIH requesting its biggest budget yet, these are the three most promising healthcare stocks to buy now.

Via InvestorPlace

QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results

March 13, 2023

From QIAGEN N.V.

Via Business Wire

Will Investors Notice Exciting Sign On Qiagen's Chart? ↗

December 20, 2022

Via Benzinga

QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug

March 09, 2023

From QIAGEN N.V.

Via Business Wire

QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing

March 01, 2023

From QIAGEN N.V.

Via Business Wire

QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework

February 14, 2023

From QIAGEN N.V.

Via Business Wire

QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups

February 07, 2023

From QIAGEN N.V.

Via Business Wire

Genetic Technologies Shares Jump After Strategic Alliance With Qiagen ↗

February 01, 2023

Genetic Technologies Limited (NASDAQ: GENE) agreed to form a strategic alliance with Qiagen NV (NYSE: QGEN) to establish and develop a 'Centre of Excellence facility in Australia.

Via Benzinga

QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs

January 17, 2023

From QIAGEN N.V.

Via Business Wire

QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast

January 17, 2023

From QIAGEN N.V.

Via Business Wire

Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories ↗

January 09, 2023

Bloomberg

Via Benzinga

QIAGEN Acquires Verogen Strengthening Its Position In Human ID / Forensics ↗

January 09, 2023

Via Benzinga

QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies

January 09, 2023

From QIAGEN

Via Business Wire

QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases

January 05, 2023

From QIAGEN N.V.

Via Business Wire

QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer

December 13, 2022

From QIAGEN N.V.

Via Business Wire

QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance

November 21, 2022

From QIAGEN N.V.

Via Business Wire

QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook

November 07, 2022

From QIAGEN N.V.

Via Business Wire

A Preview Of Qiagen's Earnings ↗

November 04, 2022

Qiagen (NYSE:QGEN) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Qiagen will report an...

Via Benzinga

QIAGEN N.V. to Release Results for Q3 2022 and Hold Webcast

October 21, 2022

From QIAGEN N.V.

Via Business Wire

Earnings Scheduled For November 7, 2022 ↗

November 07, 2022

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.

Via Benzinga

Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely ↗

October 11, 2022

One analyst doubts any deal could come to fruition. If it did, it would make sense.

Via Investor's Business Daily

Twitter May Drop Clickable Hashtags, AstraZeneca's Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11 ↗

October 11, 2022

Reuters US-China Chip War: KLA Relaxes Chip Supply To China

Via Benzinga

Bio-Rad Laboratories, Qiagen Mull Merger Of Equals ↗

October 11, 2022

Bio-Rad Laboratories Inc (NYSE: BIO) is reportedly in talks to merge with Qiagen NV (NYSE: QGEN), but any agreement isn't likely for another few weeks or more, or it may not happen at all.

Via Benzinga

FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests ↗

September 27, 2022

Via Benzinga

COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns ↗

September 23, 2022

The World Health Organization (WHO) warned that it struggles to identify and

Via Benzinga

IGI Inex Holding (UK) Becomes Strategic Investor in Quantumrock, Cementing Partnership Between Leading Global Investment Group and AI Asset Tech Frontrunners

September 16, 2022

Via ACCESSWIRE

QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System

September 15, 2022

From QIAGEN N.V.

Via Business Wire

QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug

September 14, 2022

From QIAGEN N.V.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.